SlideShare a Scribd company logo
1 of 51
Palliative care Pain in cancer patients D. Schrijvers, MD, PhD Department Medical Oncology Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Pain
Prevalence Patients (%) after curative treatment Patients (%) during anticancer treatment van den Beuken-van Everdingen et al. Ann Oncol 2007 33%  ( 95%CI 21 -  46%) 59%  (95%CI  44-73%) % Study % Study
Prevalence Patients (%) with advanced, metastatic  or terminal disease All disease stages (%) van den Beuken-van Everdingen et al. Ann Oncol 2007 64%  (95%CI 58-69%) % Study 53%  (95%CI 43-63%) % Study
Prevalence ,[object Object],Van Bosch et al.  Eur J Cancer 2009 Pijn Score Timepoint 1 N = 105 Timepoint 2 N = 90 Oncologic n=60 Non- Oncologic n=43 Oncologic n=48 Non-oncologic n=43 Absent (VAS=0) 48% 60% 56% 63% Mild (VAS 1-3) 33% 14% 18% 16% Moderate (VAS 4-6) 17% 19% 17% 19% Severe (VAS 7-10) 2% 7% 9% 2%
Prevalence ,[object Object],[object Object],[object Object],[object Object],Schrijvers D. Ann Oncol 2007
Prevalence in patients with cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],van den Beuken-van Everdingen et al. Ann Oncol 2007
Causes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Oxford Textbook of Palliative Care 2007
Classification ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Schrijvers D. Ann Oncol 2007
Classification: relation to duration Schrijvers D. Ann Oncol 2007 Type pain Acute Chronic Breakthrough Duration Short Long Short Cause Identifiable Difficult to  Sometimes identify identifiable Function Protection None None Aim treatment Treatment/ Prevention Prevention/ Prevention Treatment Side effects Acceptable Not acceptable not acceptable
Classification: relation to duration Breakthrough pain Idiopatic = stimulus independent Incident pain = stimulus dependent End-of-dose pain Failing analgesia Involuntary Voluntary Ischemia Distension hollow organs Spasm Movement  Activity
Classification: pathophysiologic mechanism ,[object Object],[object Object]
Classification: pathophysiologic mechanism ,[object Object],[object Object]
Classification: pathophysiologic mechanism ,[object Object],[object Object]
Classification: pathophysiologic mechanism ,[object Object],Gilron et al. CMAJ 2006
Evaluation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Evaluation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Evaluation ,[object Object],DN4 questionnaire
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Multidisciplinary team approach
Treatment: physical aspects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: analgesics ,[object Object],VAS 1-3 VAS 4-6 VAS 7-10
Treatment: analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Opioid receptor: genetic variability Klepstad P et al. Tidsskr Nor Laegeforen. 2005 Treatment: analgesics ,[object Object],                                                                                                                                             
Treatment: analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: opioids ,[object Object],Medication   Opioid receptor interference µ   Morphine A(1+2) a a Oxycodone A A Fentanyl A(1) a Methadone A A Hydromorphone A a Buprenorphine a Tramadol a
Treatment: opioids ,[object Object]
Treatment: opioids ,[object Object],Medication   Affinity Low High Morphine + Fentanyl + Methadone + Buprenorphine + Tramadol +
Treatment: opioids ,[object Object],Medication   Solubility Low Intermediate   High Morphine + Oxycodone + Fentanyl (L)   + Methadone (L)   + Hydromorphone   +
Treatment: opioids ,[object Object],Medication Metabolism Metabolite Codeine CYP2D6 Morphine Oxycodone CYP2D6 Morphine UGT3B7 M3G-M6G Hydromorphone UGT3B7 Fentanyl CYP3A4 Methadone CYP3A4 Tramadol CYP2D6 (poor/rapid)
Treatment: opioids ,[object Object]
Treatment: scheduling and titration of analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: scheduling and titration of analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: chronic use of analgesics ,[object Object],[object Object],[object Object]
Treatment: opioid equianalgesic table SC: subcutaneous; IV: intravenous; MR: modified release; TC: transcutaneous Medication Oral (mg) Parenteral (SC, IV)(mg) Other routes Duration (hours) Duration MR (hours) Morphine 10 2.5 3-4 12-24 Hydromorphone 1.5-2  0.8 3-4 12-24 Codeine 100 3-4 Oxycodone 4.5-6 3-4 8-12 Methadone 20 10 6-8 Fentanyl 0.1-0.2 0.12-0.25 TC: 2.5 µg/3 days 72 Tramadol 100 100 Buprenorphine 0.25 TC: 35 µg/3-4 days 72-96
Treatment: opioids ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: opioids ,[object Object],[object Object],[object Object],[object Object],Opioid Rotation Pain control possible with correct analgesics use in  80-90% of patients
Treatment: co-analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Medication Indication  Oral dose schedule Benzodiazepines Diazepam  Muscle spasm/myoclonic jerks  2-10 mg q 6-8 h Midazolam  Muscle spasm 0.3-0.5 mg/kg (SC) Spasmolytics Butylhyoscine Visceral spasm/Cramps 10-20 mg q 8 h Corticosteroids Dexamethasone Edema, inflammation 8-16 mg q 24 h Bisphosphonates Zoledronic acid Bone metastases 4 mg q 28 days IV Pamidronate Bone metastases 60 mg q 28 days IV Kg: kilogram; mg: milligram; q: every; h: hour; SC: subcutaneous, IV: intravenous Treatment: co-analgesics ,[object Object]
Treatment: co-analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: co-analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: co-analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment: co-analgesics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Undertreatment of cancer pain Deandrea et al. Ann Oncol 2008 Author Year N° patients % negative Pain Management Index (95% CI) Cleeland 1994 597 42 (38–46) Larue 1995 270 51 (45–57) Elliott 1997 314 16b, 41b Trowbridge 1997 320 38 (31–46), 35 (28–42) Saxena 1999 200 79 (73–85) de Wit 1999 313 49 (43–55) Mystakidou 2001 220 76 (70–82) Sabatowski 2001 905 13 (11–15) Beck 2001 426 31 (27–35) Shvartzman 2003 218 75 (69–81) Hyun 2003 508 41 (37–45) Di Maio 2004 752 82 (79–85) Russell 2006 864 7 (3–11), 9 (7–11) Enting 2007 244 65 (59–71)
Under-treatment of cancer pain ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Deandrea et al. Ann Oncol 2008
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Importance of multi- and interdisciplinary cooperation Neuroleptics (Tricyclic) Anti depressants Local  anesthetics Analgesics Anti- epileptics Anti- spasmotics Cortico- steroids
Resolution on the Access to Adequate Pain Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],British Medical Association 2011
Resolution on the Access to Adequate Pain Treatment ,[object Object],[object Object],[object Object],British Medical Association 2011
 

More Related Content

What's hot

Neuropathic pain management
Neuropathic pain managementNeuropathic pain management
Neuropathic pain managementdamuluri ramu
 
Pain control in Emergency Department
Pain control in Emergency DepartmentPain control in Emergency Department
Pain control in Emergency DepartmentDr.Mahmoud Abbas
 
Interventional pain management pada cancer pain dengan modalitas
Interventional pain management pada cancer pain dengan modalitasInterventional pain management pada cancer pain dengan modalitas
Interventional pain management pada cancer pain dengan modalitasGivenchy Eunike
 
Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy Ade Wijaya
 
Cancer Pain: Introduction and Medical Management
Cancer Pain: Introduction and Medical ManagementCancer Pain: Introduction and Medical Management
Cancer Pain: Introduction and Medical Managementyury
 
Neuropathic pain lecture by Dr. Rashimul haque
Neuropathic pain lecture  by Dr.  Rashimul haqueNeuropathic pain lecture  by Dr.  Rashimul haque
Neuropathic pain lecture by Dr. Rashimul haqueRashimul haque Rimon
 
Current concept for management of neuropathic pain
Current  concept  for management  of  neuropathic painCurrent  concept  for management  of  neuropathic pain
Current concept for management of neuropathic painNeurologyKota
 
Principles in cancer pain management = j ansen 2014
Principles in cancer pain management = j ansen 2014Principles in cancer pain management = j ansen 2014
Principles in cancer pain management = j ansen 2014Muhamad Ivan
 
Treatment of Neuropathic Pain
Treatment of Neuropathic PainTreatment of Neuropathic Pain
Treatment of Neuropathic PainLatoya King
 
Chemotherapy Induced Peripheral Neuropathy Handout
Chemotherapy Induced Peripheral Neuropathy HandoutChemotherapy Induced Peripheral Neuropathy Handout
Chemotherapy Induced Peripheral Neuropathy HandoutJoseph Helms
 
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?Sudhir Kumar
 
Acupuncture for fibromyalgia
Acupuncture for fibromyalgiaAcupuncture for fibromyalgia
Acupuncture for fibromyalgiaMiltiades Karavis
 
Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...
Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...
Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...epaiewonsky
 
Peripheral neuropathy - Dr Shirley Wong
Peripheral neuropathy - Dr Shirley WongPeripheral neuropathy - Dr Shirley Wong
Peripheral neuropathy - Dr Shirley WongBreaCan
 

What's hot (19)

Neuropathic pain management
Neuropathic pain managementNeuropathic pain management
Neuropathic pain management
 
Pain control in Emergency Department
Pain control in Emergency DepartmentPain control in Emergency Department
Pain control in Emergency Department
 
Interventional pain management pada cancer pain dengan modalitas
Interventional pain management pada cancer pain dengan modalitasInterventional pain management pada cancer pain dengan modalitas
Interventional pain management pada cancer pain dengan modalitas
 
Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy
 
X
XX
X
 
Cancer Pain: Introduction and Medical Management
Cancer Pain: Introduction and Medical ManagementCancer Pain: Introduction and Medical Management
Cancer Pain: Introduction and Medical Management
 
Neuropathic pain lecture by Dr. Rashimul haque
Neuropathic pain lecture  by Dr.  Rashimul haqueNeuropathic pain lecture  by Dr.  Rashimul haque
Neuropathic pain lecture by Dr. Rashimul haque
 
Current concept for management of neuropathic pain
Current  concept  for management  of  neuropathic painCurrent  concept  for management  of  neuropathic pain
Current concept for management of neuropathic pain
 
Principles in cancer pain management = j ansen 2014
Principles in cancer pain management = j ansen 2014Principles in cancer pain management = j ansen 2014
Principles in cancer pain management = j ansen 2014
 
Managing neuropathic pain
Managing neuropathic painManaging neuropathic pain
Managing neuropathic pain
 
Treatment of Neuropathic Pain
Treatment of Neuropathic PainTreatment of Neuropathic Pain
Treatment of Neuropathic Pain
 
Chemotherapy Induced Peripheral Neuropathy Handout
Chemotherapy Induced Peripheral Neuropathy HandoutChemotherapy Induced Peripheral Neuropathy Handout
Chemotherapy Induced Peripheral Neuropathy Handout
 
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
 
diabetic neuropathy
diabetic neuropathydiabetic neuropathy
diabetic neuropathy
 
Cancer pain
Cancer painCancer pain
Cancer pain
 
Acupuncture for fibromyalgia
Acupuncture for fibromyalgiaAcupuncture for fibromyalgia
Acupuncture for fibromyalgia
 
Neuropathic pain
Neuropathic painNeuropathic pain
Neuropathic pain
 
Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...
Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...
Pregabalin (Lyrica©) for the Management of Pain Associated with Trigeminal Ne...
 
Peripheral neuropathy - Dr Shirley Wong
Peripheral neuropathy - Dr Shirley WongPeripheral neuropathy - Dr Shirley Wong
Peripheral neuropathy - Dr Shirley Wong
 

Viewers also liked

MCO 2011 - Slide 36 - D. Schrijvers - Pain control
MCO 2011 - Slide 36 - D. Schrijvers - Pain controlMCO 2011 - Slide 36 - D. Schrijvers - Pain control
MCO 2011 - Slide 36 - D. Schrijvers - Pain controlEuropean School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
Opioid Pharmacology
Opioid PharmacologyOpioid Pharmacology
Opioid Pharmacologyshabeel pn
 

Viewers also liked (9)

MCO 2011 - Slide 36 - D. Schrijvers - Pain control
MCO 2011 - Slide 36 - D. Schrijvers - Pain controlMCO 2011 - Slide 36 - D. Schrijvers - Pain control
MCO 2011 - Slide 36 - D. Schrijvers - Pain control
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
Opioid Pharmacology
Opioid PharmacologyOpioid Pharmacology
Opioid Pharmacology
 

Similar to MON 2011 - Slide 32 - D. Schrijvers - Pain control

cancer pain management
cancer pain managementcancer pain management
cancer pain managementGowri Shankar
 
Perioperative pain management
Perioperative pain managementPerioperative pain management
Perioperative pain managementBelindo wirabuana
 
Cancer pain dr. varun
Cancer pain dr. varunCancer pain dr. varun
Cancer pain dr. varunVarun Goel
 
Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.guest7342323
 
What To Do When Opioids Fail
What To Do When Opioids FailWhat To Do When Opioids Fail
What To Do When Opioids FailBCAGCP
 
Chronic pain management
Chronic pain managementChronic pain management
Chronic pain managementAnkit Gajjar
 
Role of anaesthesiologist in management of cancer pain
Role of anaesthesiologist in management of cancer painRole of anaesthesiologist in management of cancer pain
Role of anaesthesiologist in management of cancer painDrUday Pratap Singh
 
Pediatric Pain Management
Pediatric Pain ManagementPediatric Pain Management
Pediatric Pain Managementyury
 
Pain Management In Nursing4 With K I W I N
Pain Management In Nursing4 With  K I W I NPain Management In Nursing4 With  K I W I N
Pain Management In Nursing4 With K I W I Ngerlam
 
Pain Final With K I W I N
Pain  Final With  K I W I NPain  Final With  K I W I N
Pain Final With K I W I Ngerlam
 
craniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.ppt
craniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.pptcraniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.ppt
craniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.pptDeniseMathre1
 
Multiple sclerosis: Medical and Nursing Managements
Multiple sclerosis: Medical and Nursing ManagementsMultiple sclerosis: Medical and Nursing Managements
Multiple sclerosis: Medical and Nursing ManagementsReynel Dan
 
Cancer Palliative Care
Cancer Palliative CareCancer Palliative Care
Cancer Palliative CareEneutron
 
Postoperative pain management
Postoperative pain management  Postoperative pain management
Postoperative pain management tanjinaeva20
 

Similar to MON 2011 - Slide 32 - D. Schrijvers - Pain control (20)

cancer pain management
cancer pain managementcancer pain management
cancer pain management
 
Cancer pain management
Cancer pain managementCancer pain management
Cancer pain management
 
cancer pain.pptx
cancer pain.pptxcancer pain.pptx
cancer pain.pptx
 
Perioperative pain management
Perioperative pain managementPerioperative pain management
Perioperative pain management
 
Cancer pain dr. varun
Cancer pain dr. varunCancer pain dr. varun
Cancer pain dr. varun
 
Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.
 
05. Cancer Pain Management.ppt
05. Cancer Pain Management.ppt05. Cancer Pain Management.ppt
05. Cancer Pain Management.ppt
 
What To Do When Opioids Fail
What To Do When Opioids FailWhat To Do When Opioids Fail
What To Do When Opioids Fail
 
Chronic pain management
Chronic pain managementChronic pain management
Chronic pain management
 
Role of anaesthesiologist in management of cancer pain
Role of anaesthesiologist in management of cancer painRole of anaesthesiologist in management of cancer pain
Role of anaesthesiologist in management of cancer pain
 
Pediatric Pain Management
Pediatric Pain ManagementPediatric Pain Management
Pediatric Pain Management
 
Pain Management In Nursing4 With K I W I N
Pain Management In Nursing4 With  K I W I NPain Management In Nursing4 With  K I W I N
Pain Management In Nursing4 With K I W I N
 
Pain Final With K I W I N
Pain  Final With  K I W I NPain  Final With  K I W I N
Pain Final With K I W I N
 
Pain leal
Pain lealPain leal
Pain leal
 
Opioid pain surgery2010
Opioid pain surgery2010Opioid pain surgery2010
Opioid pain surgery2010
 
craniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.ppt
craniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.pptcraniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.ppt
craniofacial_pain EXCELLENTSLIDES PLUS TRIGEMINAL.ppt
 
Multiple sclerosis: Medical and Nursing Managements
Multiple sclerosis: Medical and Nursing ManagementsMultiple sclerosis: Medical and Nursing Managements
Multiple sclerosis: Medical and Nursing Managements
 
Pain management
Pain managementPain management
Pain management
 
Cancer Palliative Care
Cancer Palliative CareCancer Palliative Care
Cancer Palliative Care
 
Postoperative pain management
Postoperative pain management  Postoperative pain management
Postoperative pain management
 

More from European School of Oncology

S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 
J.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the artJ.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the artEuropean School of Oncology
 
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)European School of Oncology
 
ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease
ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease
ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease European School of Oncology
 
ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies
ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies
ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies European School of Oncology
 
ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...
ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...
ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...European School of Oncology
 

More from European School of Oncology (20)

1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 
J.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the artJ.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the art
 
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
 
G. Ceresoli - Lung cancer - State of the art
G. Ceresoli - Lung cancer - State of the artG. Ceresoli - Lung cancer - State of the art
G. Ceresoli - Lung cancer - State of the art
 
ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease
ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease
ABC1 - O. Pagani - State-of-the-art HT treatment in ER+ disease
 
ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies
ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies
ABC1 - G.W. Sledge - Resistance to anti-HER2 therapies
 
ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...
ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...
ABC1 - N. Houssami - Overview of imaging tests for assessment of metastases i...
 
ABC1 - F. Cardoso - Opening and introduction
ABC1 - F. Cardoso - Opening and introductionABC1 - F. Cardoso - Opening and introduction
ABC1 - F. Cardoso - Opening and introduction
 

MON 2011 - Slide 32 - D. Schrijvers - Pain control

  • 1. Palliative care Pain in cancer patients D. Schrijvers, MD, PhD Department Medical Oncology Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
  • 2.
  • 3. Prevalence Patients (%) after curative treatment Patients (%) during anticancer treatment van den Beuken-van Everdingen et al. Ann Oncol 2007 33% ( 95%CI 21 - 46%) 59% (95%CI 44-73%) % Study % Study
  • 4. Prevalence Patients (%) with advanced, metastatic or terminal disease All disease stages (%) van den Beuken-van Everdingen et al. Ann Oncol 2007 64% (95%CI 58-69%) % Study 53% (95%CI 43-63%) % Study
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. Classification: relation to duration Schrijvers D. Ann Oncol 2007 Type pain Acute Chronic Breakthrough Duration Short Long Short Cause Identifiable Difficult to Sometimes identify identifiable Function Protection None None Aim treatment Treatment/ Prevention Prevention/ Prevention Treatment Side effects Acceptable Not acceptable not acceptable
  • 11. Classification: relation to duration Breakthrough pain Idiopatic = stimulus independent Incident pain = stimulus dependent End-of-dose pain Failing analgesia Involuntary Voluntary Ischemia Distension hollow organs Spasm Movement Activity
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37. Treatment: opioid equianalgesic table SC: subcutaneous; IV: intravenous; MR: modified release; TC: transcutaneous Medication Oral (mg) Parenteral (SC, IV)(mg) Other routes Duration (hours) Duration MR (hours) Morphine 10 2.5 3-4 12-24 Hydromorphone 1.5-2 0.8 3-4 12-24 Codeine 100 3-4 Oxycodone 4.5-6 3-4 8-12 Methadone 20 10 6-8 Fentanyl 0.1-0.2 0.12-0.25 TC: 2.5 µg/3 days 72 Tramadol 100 100 Buprenorphine 0.25 TC: 35 µg/3-4 days 72-96
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46. Undertreatment of cancer pain Deandrea et al. Ann Oncol 2008 Author Year N° patients % negative Pain Management Index (95% CI) Cleeland 1994 597 42 (38–46) Larue 1995 270 51 (45–57) Elliott 1997 314 16b, 41b Trowbridge 1997 320 38 (31–46), 35 (28–42) Saxena 1999 200 79 (73–85) de Wit 1999 313 49 (43–55) Mystakidou 2001 220 76 (70–82) Sabatowski 2001 905 13 (11–15) Beck 2001 426 31 (27–35) Shvartzman 2003 218 75 (69–81) Hyun 2003 508 41 (37–45) Di Maio 2004 752 82 (79–85) Russell 2006 864 7 (3–11), 9 (7–11) Enting 2007 244 65 (59–71)
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.  

Editor's Notes

  1. 04/14/11
  2. 04/14/11
  3. 04/14/11
  4. van den Beuken-van Everdingen MH,
  5. 04/14/11
  6. 04/14/11
  7. 04/14/11
  8. 04/14/11
  9. 04/14/11
  10. 04/14/11
  11. 04/14/11
  12. Neuropathic pain arises following nerve injury or dysfunction. A: After nerve damage, transcription and axonal trafficking of sodium channels to the site of injury is increased, with concomitant attenuation of potassium channels. The altered expression of ion channels results in neurons becoming hyperexcitable and generating ectopic activity, which is thought to lead to the genesis of spontaneous and paroxysmal pain. B: At the cell body of primary afferent neurons within the dorsal root ganglia (DRG), sympathetic neuronal sprouting occurs and may account for sympathetically maintained pain. C: Peripheral nerve injury causes a multitude of changes in gene transcription and activation of various kinases and proteins, including enhanced N-methyl-D-aspartate (NMDA) receptor activity. However, nerve injury also elicits hypertrophy and activation of glial cells, including microglia within the grey matter of the spinal cord. Microglia express P2X4 purinergic receptors, allowing them to be activated by adenosine triphosphate (ATP). Following activation, microglia release various pronociceptive cytokines, such as interleukin-1 (IL-1), tumour necrosis factor alpha (TNF- ) and neurotrophins, including brain-derived neurotrophic factor, which in turn exacerbates nociceptive transmission and contributes to the sensitization and maintenance of neuropathic pain. Note: Aß = A beta neuron, A = A delta neuron, C = C nociceptor, 5HT = serotonin, KCC2 = chloride transporter, NA = noradrenaline, Nav = sodium channel, NO = nitric oxide, Kv = potassium channel, PGs = prostaglandins, PKs = protein kinases, P2X4 = purinergic receptor. 04/14/11
  13. 04/14/11
  14. 04/14/11
  15. 04/14/11
  16. 04/14/11
  17. 04/14/11
  18. 04/14/11
  19. 04/14/11
  20. 04/14/11
  21. 04/14/11
  22. 04/14/11
  23. 04/14/11
  24. 04/14/11
  25. 04/14/11
  26. 04/14/11
  27. 04/14/11
  28. 04/14/11
  29. 04/14/11
  30. 04/14/11
  31. 04/14/11
  32. 04/14/11
  33. 04/14/11
  34. 04/14/11
  35. 04/14/11
  36. 04/14/11
  37. 04/14/11
  38. 04/14/11
  39. 04/14/11
  40. 04/14/11
  41. 04/14/11
  42. 04/14/11
  43. 04/14/11